Human Genome Sciences and GlaxoSmithKline have begun dosing for BLISS-52, the second of two Phase III trials of LymphoStat-B in patients with active systemic lupus erythematosus (SLE). Dosing in BLISS-76, the first Phase III trial of the drug, began in February 2007. LymphoStat-B is being developed by the companies under a definitive development and commercialization agreement initiated in August 2006. “We believe that LymphoStat-B could address the significant medical need of patients ...